Durect Corp. | Mutual Funds
Mutual Funds that own Durect Corp.
Vanguard Total Stock Market Index Fund
3,881,717
2.4%
158,357
0%
07/31/2018
iShares Russell 2000 ETF
3,280,578
2.02%
-1,752
0.01%
09/06/2018
Vanguard Extended Market Index Fund
2,184,963
1.35%
0
0%
07/31/2018
iShares Russell 2000 Growth ETF
1,533,835
0.95%
0
0.02%
09/06/2018
Fidelity Spartan Extended Market Index Fund
716,930
0.44%
0
0%
07/31/2018
Bridgeway Ultra Small Company Market Fund
708,600
0.44%
250,000
0.21%
12/31/2017
iShares Micro Cap ETF
420,151
0.26%
0
0.05%
09/06/2018
CREF Stock Account
397,170
0.25%
0
0%
03/31/2018
Schwab Small Cap Index Fund
301,576
0.19%
38,100
0.01%
06/30/2018
Fidelity Spartan Small Cap Index Fund
299,741
0.19%
16,805
0.01%
04/30/2018
| Address |
10260 Bubb Road
Cupertino California 95014
United States
|
|
Employees
|
- |
| Website |
http://www.durect.com |
| Updated |
07/08/2019 |
| DURECT Corp. is a biopharmaceutical company, which engages in the research, development, and manufacturing of pharmaceutical products. Its product pipeline consists of multiple investigational drug candidates in clinical development. It offers DUR-928, which focuses on lipid homeostasis, inflammation, and cell survival; POSIMIR, which is an analgesic product intended to deliver bupivacaine to provide pain relief after surgery; and REMOXY ER, which provides investigational extended release pain relief. |
